Maze Therapeutics (NASDAQ:MAZE) Releases Quarterly Earnings Results, Meets Expectations

Maze Therapeutics (NASDAQ:MAZE) issued its quarterly earnings results on Tuesday. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76), Zacks reports.

Maze Therapeutics Stock Down 0.7%

Maze Therapeutics stock opened at $27.11 on Wednesday. The company has a fifty day simple moving average of $27.63 and a 200 day simple moving average of $33.32. Maze Therapeutics has a 1-year low of $12.81 and a 1-year high of $53.65. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The company has a market cap of $1.50 billion, a P/E ratio of -11.06 and a beta of 2.21.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MAZE shares. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday. Truist Financial reduced their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $66.00.

Insider Buying and Selling

In other Maze Therapeutics news, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. This represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the sale, the insider owned 26,250 shares of the company’s stock, valued at approximately $717,675. This represents a 22.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 141,470 shares of company stock worth $3,902,714. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds have recently bought and sold shares of the company. Invesco Ltd. increased its position in Maze Therapeutics by 1.5% during the fourth quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock worth $5,553,000 after buying an additional 1,971 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Maze Therapeutics by 589.3% in the fourth quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock valued at $7,438,000 after buying an additional 153,487 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Maze Therapeutics by 22.9% during the 4th quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock worth $1,368,000 after acquiring an additional 6,154 shares during the period. Wellington Management Group LLP bought a new position in shares of Maze Therapeutics during the 4th quarter worth approximately $2,536,000. Finally, Squadron Capital Management LLC acquired a new position in shares of Maze Therapeutics during the 4th quarter worth approximately $20,301,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.